Britain’s competition watchdog on Tuesday said it was investigating the planned purchase of US biotech company Alexion by COVID vaccine-maker AstraZeneca in a deal worth $39 billion.

In a brief statement, the Competition and Markets Authority said it was looking at whether the deal would “result in a substantial lessening of competition within any market or markets in the United Kingdom for goods or services”.

Source: Read Full Article